These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23489201)

  • 21. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.
    Gareb B; Dijkstra G; Kosterink JGW; Frijlink HW
    Int J Pharm; 2019 Jan; 554():366-375. PubMed ID: 30414898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect.
    Verma P; Prajapati SK; Yadav R; Senyschyn D; Shea PR; Trevaskis NL
    Mol Pharm; 2016 Nov; 13(11):3688-3699. PubMed ID: 27632682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system.
    Pradal J; Zuluaga MF; Maudens P; Waldburger JM; Seemayer CA; Doelker E; Gabay C; Jordan O; Allémann E
    Eur J Pharm Biopharm; 2015 Jun; 93():110-7. PubMed ID: 25836052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers.
    Haesslein A; Ueda H; Hacker MC; Jo S; Ammon DM; Borazjani RN; Kunzler JF; Salamone JC; Mikos AG
    J Control Release; 2006 Aug; 114(2):251-60. PubMed ID: 16872709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral formulations of budesonide: a novel treatment for inflammatory bowel disease.
    Svoboda RP; Patel DH; Olden KW
    Drugs Today (Barc); 2008 Nov; 44(11):857-63. PubMed ID: 19180263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.
    Kluza E; Yeo SY; Schmid S; van der Schaft DW; Boekhoven RW; Schiffelers RM; Storm G; Strijkers GJ; Nicolay K
    J Control Release; 2011 Apr; 151(1):10-7. PubMed ID: 21130819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review Article: Fabricated Microparticles: An Innovative Method to Minimize the Side Effects of NSAIDs in Arthritis.
    Abadi SS; Moin A; Veerabhadrappa GH
    Crit Rev Ther Drug Carrier Syst; 2016; 33(5):433-488. PubMed ID: 27910742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance.
    Butoescu N; Jordan O; Doelker E
    Eur J Pharm Biopharm; 2009 Oct; 73(2):205-18. PubMed ID: 19545624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid nanoparticles as drug/gene delivery systems to the retina.
    del Pozo-Rodríguez A; Delgado D; Gascón AR; Solinís MÁ
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):173-88. PubMed ID: 23286300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethyl cellulose nanocarriers and nanocrystals differentially deliver dexamethasone into intact, tape-stripped or sodium lauryl sulfate-exposed ex vivo human skin - assessment by intradermal microdialysis and extraction from the different skin layers.
    Döge N; Hönzke S; Schumacher F; Balzus B; Colombo M; Hadam S; Rancan F; Blume-Peytavi U; Schäfer-Korting M; Schindler A; Rühl E; Skov PS; Church MK; Hedtrich S; Kleuser B; Bodmeier R; Vogt A
    J Control Release; 2016 Nov; 242():25-34. PubMed ID: 27394682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer.
    Ozbakir B; Crielaard BJ; Metselaar JM; Storm G; Lammers T
    J Control Release; 2014 Sep; 190():624-36. PubMed ID: 24878183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone-diclofenac loaded polylactide nanoparticles: Preparation, release and anti-inflammatory activity.
    Assali M; Shawahna R; Dayyeh S; Shareef M; Alhimony IA
    Eur J Pharm Sci; 2018 Sep; 122():179-184. PubMed ID: 29981402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of hyperbranched core-multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa.
    Jager J; Obst K; Lohan SB; Viktorov J; Staufenbiel S; Renz H; Unbehauen M; Haag R; Hedtrich S; Teutloff C; Meinke MC; Danker K; Dommisch H
    J Periodontal Res; 2018 Feb; 53(1):57-65. PubMed ID: 28898420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
    Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [DDS preparations of drugs for inflammatory bowel disease].
    Takada K
    Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New developments and opportunities in oral mucosal drug delivery for local and systemic disease.
    Hearnden V; Sankar V; Hull K; Juras DV; Greenberg M; Kerr AR; Lockhart PB; Patton LL; Porter S; Thornhill MH
    Adv Drug Deliv Rev; 2012 Jan; 64(1):16-28. PubMed ID: 21371513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacology of glucocorticoids and ENT pathology].
    Devillier P
    Presse Med; 2001 Dec 22-29; 30(39-40 Pt 2):59-69. PubMed ID: 11819915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds.
    Conte R; Marturano V; Peluso G; Calarco A; Cerruti P
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28350317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled release technologies for drug delivery.
    Brayden DJ
    Drug Discov Today; 2003 Nov; 8(21):976-8. PubMed ID: 14643159
    [No Abstract]   [Full Text] [Related]  

  • 40. Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases.
    Turjeman K; Barenholz Y
    J Drug Target; 2016 Nov; 24(9):805-820. PubMed ID: 27750439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.